Corcept Endocrinology
Equibles does not estimate personal net worth.
Get an email with a short summary when Corcept Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get CORT alertsAbout Corcept Endocrinology
The proxy statement of Corcept Therapeutics Inc reports total compensation of $3,908,931 for Corcept Endocrinology in fiscal 2023, including a base salary of $601,583. Disclosed compensation is on record for 2 fiscal years. Corcept Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Corcept Therapeutics Inc includes Joseph K. Belanoff (CEO and Board Member), James N. Wilson (Chairman and Board Member), Atabak Mokari (CFO) and 7 others.
Affiliation history
-
Corcept Therapeutics Inc (CORT)
Proxy statement
Current
Company network
Leadership on record at Corcept Therapeutics Inc
- Joseph K. Belanoff CEO, Board Member
- James N. Wilson Chairman, Board Member
- Atabak Mokari CFO
- Joshua M. Murray CFO, Head of Investor Relations, Board Member
- Daniel N. Swisher COO
- J.D. Lyon Chief Accounting Officer
- Joseph D. Lyon Chief Accounting Officer
- Daniel N. Swisher, Jr. Board Member
- David L. Mahoney Board Member
- G. Leonard Baker, Jr. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Corcept Therapeutics Inc (CORT) | — | $601,583 | $3,908,931 |
| 2022 | Corcept Therapeutics Inc (CORT) | — | $572,917 | $3,714,056 |
Recent activity
No call appearances or filed executive changes recorded yet.